Theophylline Extended-Release Tablets — Class II drug recall D-0111-2027
Ongoing recall by Brandywine Pharmaceuticals, LLC, reported 2026-11-04, distributed nationwide. CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory
| Recall number | D-0111-2027 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Brandywine Pharmaceuticals, LLC, West Chester, PA, United States |
| Recall initiated | 2026-10-06 |
| Classified | 2026-10-29 |
| Reported by FDA | 2026-11-04 |
| Distributed | Nationwide (US) |
| Reason classes | cgmp, specification failure |
| NDC | 71321-0501-10 |
| Lot numbers | 405620 |
| Expiration dates | 2028-03-31 |
Product
Theophylline Extended-Release Tablets, 200 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-501-10.
Reason for recall
CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0111-2027. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-11-10. Not affiliated with or endorsed by FDA. Not medical or legal advice.